(1R,2R,3S,5R)-3-(7-(((1S,2R)-2-(3,4-difluorophenyl)cyclopropyl)amino)-5-(propylthio)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl)-5-(2-hydroxyethoxy)cyclopentane-1,2-diol

98%

Reagent Code: #232186
fingerprint
CAS Number 2096989-55-6

science Other reagents with same CAS 2096989-55-6

blur_circular Chemical Specifications

scatter_plot Molecular Information
Weight 522.57 g/mol
Formula C₂₃H₂₈F₂N₆O₄S
inventory_2 Storage & Handling
Storage 2-8°C

description Product Description

Ticagrelor is a selective, direct-acting inhibitor of the P2Y12 ADP-receptor on platelets, used to reduce the risk of thrombotic cardiovascular events in patients with acute coronary syndrome (ACS) or a history of myocardial infarction. It reversibly binds to the P2Y12 receptor, preventing ADP-induced platelet aggregation and thereby inhibiting thrombus formation. This leads to decreased rates of cardiovascular death, myocardial infarction, and stroke. Administered orally as a tablet, typically in combination with low-dose aspirin for chronic therapy.

shopping_cart Available Sizes & Pricing

Size Availability Unit Price Quantity
inventory 10mg
10-20 days ฿140,000.00

Cart

No products

Subtotal: 0.00
Total 0.00 THB
Cart Checkout
(1R,2R,3S,5R)-3-(7-(((1S,2R)-2-(3,4-difluorophenyl)cyclopropyl)amino)-5-(propylthio)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl)-5-(2-hydroxyethoxy)cyclopentane-1,2-diol
No image available
Ticagrelor is a selective, direct-acting inhibitor of the P2Y12 ADP-receptor on platelets, used to reduce the risk of thrombotic cardiovascular events in patients with acute coronary syndrome (ACS) or a history of myocardial infarction. It reversibly binds to the P2Y12 receptor, preventing ADP-induced platelet aggregation and thereby inhibiting thrombus formation. This leads to decreased rates of cardiovascular death, myocardial infarction, and stroke. Administered orally as a tablet, typically in combinati
Ticagrelor is a selective, direct-acting inhibitor of the P2Y12 ADP-receptor on platelets, used to reduce the risk of thrombotic cardiovascular events in patients with acute coronary syndrome (ACS) or a history of myocardial infarction. It reversibly binds to the P2Y12 receptor, preventing ADP-induced platelet aggregation and thereby inhibiting thrombus formation. This leads to decreased rates of cardiovascular death, myocardial infarction, and stroke. Administered orally as a tablet, typically in combination with low-dose aspirin for chronic therapy.
Mechanism -
Appearance -
Longevity -
Strength -
Storage -
Shelf Life -
Allergen(s) -
Dosage (Range) -
Recommended Dosage -
Dosage (Per Day) -
Recommended Dosage (Per Day) -
Mix Method -
Heat Resistance -
Stable in pH range -
Solubility -
Product Types -
INCI -

Purchase History for

Loading purchase history...